The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $32 from $39 and keeps an Equal Weight rating on the shares. The firm ...

Shares of Moderna ( MRNA -9.35%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m. ET and was down as much ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Shares of Moderna and other vaccine makers dropped after the FDA's vaccine chief announced his resignation. Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger drugmakers, ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year. More recently, the conspicuous ...